Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Dosing Regimens of MEMP1972A in Adults With Allergic Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids and a Second Controller (COSTA)
Brief Summary: This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of 3 dosing regimens of MEMP1972A in patients with allergic asthma who remain inadequately controlled on chronic therapy with high dose inhaled corticosteroids and a second controller medication.Patients will be randomized to 4 Arms to receive subcutaneous repeating dose of either MEMP1972A 150 mg, 300 mg, or 450 mg, or placebo. Patients will continue their usual asthma medication throughout the study. Anticipated time on study treatment is 36 weeks, with a 48-week follow-up.


Options:
A: Arm Label: Placebo (for Dupilumab); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Dupilumab), Drug: Fluticasone/Salmeterol combination therapy, Drug: Fluticasone monotherapy, Drug: Albuterol, Drug: Levalbuterol | Arm Label: Dupilumab 300 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Fluticasone/Salmeterol combination therapy, Drug: Fluticasone monotherapy, Drug: Albuterol, Drug: Levalbuterol | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 300 mg qw | Intervention Type: DRUG; Name: Placebo (for Dupilumab); Assigned to Arm(s): Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Fluticasone/Salmeterol combination therapy; Assigned to Arm(s): Dupilumab 300 mg qw, Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Fluticasone monotherapy; Assigned to Arm(s): Dupilumab 300 mg qw, Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Albuterol; Assigned to Arm(s): Dupilumab 300 mg qw, Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Levalbuterol; Assigned to Arm(s): Dupilumab 300 mg qw, Placebo (for Dupilumab)
B: Arm Label: AMG 317 75 mg; Type: EXPERIMENTAL; Interventions: Biological: AMG 317 75 mg | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: AMG 317 300 mg; Type: EXPERIMENTAL; Interventions: Biological: AMG 317 300 mg | Arm Label: AMG 317 150 mg; Type: EXPERIMENTAL; Interventions: Biological: AMG 317 150 mg | Intervention Type: BIOLOGICAL; Name: AMG 317 75 mg; Assigned to Arm(s): AMG 317 75 mg | Intervention Type: BIOLOGICAL; Name: AMG 317 150 mg; Assigned to Arm(s): AMG 317 150 mg | Intervention Type: BIOLOGICAL; Name: AMG 317 300 mg; Assigned to Arm(s): AMG 317 300 mg | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Arm
C: Arm Label: Mepolizumab Arm; Type: EXPERIMENTAL; Interventions: Biological: Mepolizumab | Intervention Type: BIOLOGICAL; Name: Mepolizumab; Assigned to Arm(s): Mepolizumab Arm
D: Arm Label: MEMP1972A 150 mg; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A | Arm Label: MEMP1972A 300 mg; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A | Arm Label: MEMP1972A 450 mg; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: MEMP1972A; Assigned to Arm(s): MEMP1972A 300 mg | Intervention Type: DRUG; Name: MEMP1972A; Assigned to Arm(s): MEMP1972A 450 mg | Intervention Type: DRUG; Name: MEMP1972A; Assigned to Arm(s): MEMP1972A 150 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: D